Considerable funding is needed to complete clinical research, before submitting a New Drug Application to the U.S. Food & Drug Administration. MAPS’ primary goal is to complete funding for our Phase 3 trials of MDMA-assisted psychotherapy for the treatment of PTSD. We have now raised $26.7 million of the $26.7 million needed for our upcoming Phase 3 clinical trials to make MDMA-assisted psychotherapy a legal prescription treatment for PTSD in the U.S. The final $500,000 was pledged by Dr. Richard Rockefeller’s two children, Clay and Rebecca, and 7 of their cousins.
MAPS is currently seeking $5 million for European Medicines Agency (EMA) trials to supplement the data gathered for the FDA, with $420,000 already raised and $4.6 million still to go. MAPS will have a clearer estimate of costs for Phase 3 EMA trials after we complete our negotiations with EMA. Supporters of MAPS’ European research have a special opportunity to have their gifts matched since MAPS has received a $500,000 matching grant for EMA with $210,000 already raised (and $210,000 matched) and $290,000 still to be matched.
We extend a special thanks to those who so generously supported MAPS last month:
- Hilary Silver ($10,000)
- Bequest of Tim Butcher ($2,701)
- Adam Growald ($1,000)
- Shawn Joyce ($1,000)
- Shawn Wylie ($1,000)
- Thomas Shanks ($1,000)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major non-family foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate